Skip to main content
. 2019 Apr;11(4):1397–1409. doi: 10.21037/jtd.2019.03.76

Figure 2.

Figure 2

Intracranial efficacy of ALK inhibitors. Pooled intracranial overall response rate (A), overall complete remission rate (B), and disease control rate (C) from single-arm studies; pooled odds ratio for intracranial objective response rate (D) and hazard ratio for intracranial progression-free survival (E) from randomized studies. ALK, anaplastic lymphoma kinase.